• Insulet sustainability report outlined strategy to scale diabetes technology while reducing environmental footprint, with focus on access, resilient manufacturing, circular product design.
• 2025 annual revenue reported at USD 2.7 billion; full-time workforce grew to more than 5,400 globally, up 38% versus 2024; Omnipod products sold in 25 countries.
• Omnipod 5 expansion cited across nine new markets; report highlighted integration progress with Dexcom G7, Abbott FreeStyle Libre 2 Plus.
• Environmental initiatives centered on reducing packaging materials, expanding Pod takeback programs to more than 90% of customers globally; U.S. Pod recycling program expanded to all 50 states.
• Pipeline update flagged FDA 510(k) clearance in December 2025 for Omnipod 5 algorithm enhancements, including 100 mg/dL target glucose option; U.S. launch targeted for first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.